Influence of interferon-beta therapy switching on neutralizing antibody titres: Results from the Austrian Switch Study

Multiple Sclerosis

Volumn 15, Issue 12, 2009, Pages 1481-1488

  Gneiss, Claudia ^a   Koudouovoh Tripp, Pia Maria ^a   Ropele, Stefan ^b   Gotwald, Thaddäus ^a   Ehling, Rainer ^a   Lutterotti, Andreas ^c   Aichner, Franz ^d   Ladurner, Gunther ^e   Eggers, Christian ^f   Schautzer, Franz ^a   Künz, Bettina ^a   Millonig, Alban ^a   Aspeck, Engelbert ^b   Reindl, Markus ^a   Berger, Thomas ^a   Fazekas, Franz ^b   Deisenhammer, Florian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c District Neurological Clinic   (Austria)

^d PARACELSUS MEDICAL UNIVERSITY   (Austria)

^e Konventhospital Barmherzige Bruder Linz   (Austria)

^f Villach General Hospital   (Austria)

Author keywords

Biological markers; Clinical trial; Interferon beta; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; METHYLPREDNISOLONE; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SUBSTITUTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBODIES, NEUTRALIZING; AUSTRIA; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PULSE THERAPY, DRUG; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 72749127602     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509347153     Document Type: Article

References (23)

1. IFNB multiple sclerosis study group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 ; 43: 655-661.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) [published erratum appears in Ann Neurol 1996; 40: 480]. Ann Neurol 1996 ; 39: 285-294.
3. Paty DW, Li DK UBC MS / MRI Study group and IFNB multiple sclerosis study group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 ; 43: 662-667.
4. Prisms. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998 ; 352: 1498-1504.
5. Gneiss C., Tripp P., Reichartseder F., et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler 2006 ; 12: 731-737.
6. Sorensen PS, Deisenhammer F., Duda P., et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005 ; 12: 817-827.
7. Namaka M., Pollitt-Smith M., Gupta A., et al. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis. Curr Med Res Opin 2006 ; 22: 223-239.
8. Sorensen PS, Ross C., Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003 ; 362: 1184-1191.
9. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS / MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996 ; 47: 889-894.
10. The PRISMS Study group and The University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001 ; 56: 1628-1636.
11. Gneiss C., Reindl M., Lutterotti A., et al. Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 2004 ; 10: 507-510.
12. Sorensen PS, Koch-Henriksen N., Ross C., Clemmesen KM, Bendtzen K. The Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005 ; 65: 33-39.
13. Herndon RM, Jacobs LD, Coats ME, et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Int J MS Care 1999 ; 1: 2.
14. Perini P., Facchinetti A., Bulian P., et al. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 2001 ; 12: 56-61.
15. Pozzilli C., Gasperini C., Mainero R., et al. Methylprednisolone in addition to interferon beta-1b to suppress the development of NABs in multiple sclerosis. Eur J Neurol 1999 ; 6: 51.
16. Pungor E., Files JG, Gabe JD, et al. A novel bioassay for the determination of neutralizing antibodies to IFN-β1b. J Interferon Cytokine Res 1998 ; 18: 1025-1030.
17. Kawade Y. An analysis of neutralization reaction of interferon by antibody: a proposal on the expression of neutralization titer. J Interferon Res 1980 ; 1: 61-70.
18. Smith SM, Zhang Y., Jenkinson M., et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002 ; 17: 479-489.
19. Pozzilli C., Antonini G., Bagnato F., et al. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta 1 b: a randomized trial in multiple sclerosis. J Neurol 2002 ; 249: 50-56.
20. Hesse D., Frederiksen JL, Koch-Henriksen N., et al. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-beta. Eur J Neurol 2009 ; 16: 43-47.
21. Antonelli G., Simeoni E., Bagnato F., et al. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci 1999 ; 168: 131-136.
22. Cohen BA, Oger J., Gagnon A., Giovannoni G. The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci 2008 ; 275: 7-17.
23. Sorensen PS, Koch-Henriksen N., Bendtzen K. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis? Mult Scler 2007 ; 13: 616-621.